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selective B cell therapy) + methotrexate [MTX] as an alternative
for the treatment of patients with an inadequate response to
anti-tumour necrosis factor [TNF] therapies in rheumatoid
arthritis [RA] in The Netherlands [NL]. This analysis was per-
formed as part of a reimbursement request. Currently RTX is
reimbursed according to the Dutch Expensive Hospital Drug Act.
METHODS: A cost-effectiveness model was developed to evalu-
ate the societal costs and clinical outcomes of a standard Dutch
treatment sequence either with or without RTX + MTX. The
model uses Monte Carlo simulation to generate 10,000 random
RA patients who start with 2nd line treatment after an inad-
equate response to TNF therapy + MTX. Baseline patient char-
acteristics were taken from the RTX registration study, REFLEX.
Efﬁcacy data were taken from published literature and were
placebo-adjusted to minimise bias from cross-trial comparisons.
Dutch observational data were collected in order to determine
local treatment patterns and resource utilisation data. Both direct
and indirect medical costs were based on ofﬁcial price lists
(2005). Costs and beneﬁts were discounted at 4% and 1.5%,
respectively. RESULTS: The average lifetime treatment costs per
patient in NL were €131,531 for the current treatment sequence
and €141,544 when RTX + MTX was added. QALYs gained
were 3.76 for the current treatment sequence and 4.4 when
RTX + MTX was added. The incremental cost-effectiveness ratio
for inclusion of RTX + MTX in the current treatment sequence
was €13,903/QALY. CONCLUSION: Adding RTX + MTX to
the current treatment sequence is predicted to increase QALYs
with a slight increase in overall lifetime costs for the society.
These favourable outcomes are driven by the lower annual drug
therapy costs compared with other biological alternatives.
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CHANGES IN BODYWEIGHT AND ASSOCIATED DOSING
REQUIREMENTS FOR RHEUMATOID ARTHRITIS PATIENTS
RECEIVING INFLIXIMAB—RESULTS FROM ANALYSIS OFTHE
BRITISH SOCETY FOR RHEUMATOLOGY’S BIOLOGICS
REGISTER (BSRBR)
Gibbons CJ, Morris J,Abhyankar B
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OBJECTIVES: To proﬁle the weight change observed in rheuma-
toid arthritis (RA) patients receiving inﬂiximab, in order to
understand the expected change in their dosing requirements
over time on treatment. METHODS: A total 3211 RA patients
(2436 males [24%], 775 females [76%]) with valid bodyweight
and follow-up measurements from the BSRBR were analysed.
Weight change was initially modelled by follow-up (FUP)
number using ordinary least-squares linear regression adjusted
for sex and patient’s total number of visits. Standard errors were
adjusted for clustering on study ID. RESULTS: The main analysis
modelled FUP as a categorical variable. This analysis showed
that the change in average bodyweight did not follow a steady
slope, but rather was characterized by a rapid, statistically sig-
niﬁcant increase of about 1 kg on the ﬁrst visit after baseline
followed by a slow, uneven and statistically nonsigniﬁcant
upward trend over subsequent follow-up visits. This modelling
technique gave a signiﬁcantly better ﬁt (p = 0.006) over that
possible if treating follow-up number as a continuous variable.
To test for possible biases attributable to drop-out, the analysis
was repeated in several subsets of patients who had all completed
the same number of follow-up visits. Despite statistically nonsig-
niﬁcant or statistically borderline estimates in these subsets, the
ﬁndings were similar to those reported in the main results. CON-
CLUSION: Translating observed bodyweight into an expected
number of vials required at each visit using basic 3 mg/kg dosing
shows that the observed weight gain in the BSRBR’s inﬂiximab
patients does not correspond to a statistically signiﬁcant change
in the total number of vials of inﬂiximab required. Although the
dosing in real-life clinical practice tends to vary, the results of this
analysis demonstrate that the weight gain observed during inﬂix-
imab treatment of RA patients is unlikely to have an indepen-
dent, critical impact on the resource implications for these
patients as their treatment continues.
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COST-EFFECTIVENESS OF BONE DENSITOMETRY SCREENING
COMBINED WITH ALENDRONATETHERAPY FORTHOSE
WHO HAVE OSTEOPOROSIS
Hiligsmann M, Bruyère O, Ethgen O, Reginster JY
University of Liège, Liège, Belgium
OBJECTIVES: To evaluate the cost-effectiveness of bone densi-
tometry screening for Belgian women aged 55 and older com-
bined with 5 years Alendronate therapy in osteoporotic women
(femoral neck t-score -2.5) versus no screening and no treat-
ment. METHODS: A microsimulation Markov model was devel-
oped. The model used a lifetime horizon, a Belgian societal
perspective and recorded the full patient history by the use of
tracker variables. Each prior fracture had an impact on transition
probabilities, costs and QALY level. All the model parameters
were selected from Belgian literature when available and from
systematic literature review otherwise. Analyses were realized at
the ages of 55, 60, 65, 70, 75, 80 and 85 years and for women
with 0 to 4 clinical risk factors. Sensitivity analyses were run on
persistence level. RESULTS: Costs per QALY gained for the
screen and treat strategy versus no intervention with optimal
persistence and no clinical risk factor were €49,711, €25,392 and
€10,487 for the ages of 55, 65 and 75 years respectively. With
realistic persistence, these values were respectively €61,373,
€35,780 and €14,302. With one clinical risk factor and optimal
persistence, these values were €31,320, €11,507 and cost-saving.
And with two clinical risk factors, these values were €18,206,
€2,588 and cost-saving. CONCLUSION: Universal bone densi-
tometry followed by Alendronate treatment in the presence of
osteoporosis seems highly cost-effective (cost per QALY gained
€30,000) for women aged 65 and older (with optimal persis-
tence), for women aged 70 and older (with realistic persistence)
and for women with at least one clinical risk factor aged 60 or
older (even under realistic persistence assumption). We con-
cluded that screening individuals with or more clinical risk
factors is more cost-effective than universal screening and should
be recommended.
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OBJECTIVES: To estimate, from the hospital perspective, the
cost effectiveness of FOND versus ENOX for prevention and
treatment of VTE in MOSLL patients in Germany (42% with
total hip replacement, 33% with total knee replacement, 25%
with hip-fracture surgery). METHODS: The incremental cost-
effectiveness ratio ‘additional cost for FOND per clinical VTE
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avoided versus ENOX’ was quantiﬁed using a modelling
approach based on decision-tree technique synthesising pub-
lished data and a hospital survey. Safety and efﬁcacy values of
VTE prevention with the comparators were taken from the
EPHESUS [Lassen et al. Lancet 2002], PENTAMAKS [Bauer
et al. NEJM 2001] and PENTHIFRA [Eriksson et al. NEJM
2001] trials. Data on resource utilization (staff, drugs, materials,
laboratory, and equipment) during thromboprophylaxis, diagno-
sis and treatment came from the hospital survey. Resources were
valued in internal hospital prices as of the ﬁrst quarter of 2007.
The evaluation exclusively encompassed inpatient days for
thromboprophylaxis and treatment of VTE and major bleed
during the MOSLL-related hospital stay. RESULTS: In the base-
case analysis, FOND dominated ENOX: cost savings of €3430
were obtained and 11.8 clinical VTE were avoided by FOND
versus ENOX, each per 1000 patients. In comprehensive sensi-
tivity analyses, using impact analysis and Monte Carlo simula-
tion, the robustness of these results was tested. The rate of
prophylaxis-related bleeding with FOND (RPBF) had the great-
est impact on the savings. FOND remained cost-saving in 61%
and 77% of 10,000 iterations with the ﬁrst FOND injection 6
hours after surgical closure (RPBF = 0.028) or the morning after
surgery (RPBF = 0.019), respectively. FOND remained more
effective than ENOX without exception: after 10,000 iterations,
between 4.6 and 21.2 clinical VTE were avoided by FOND
versus ENOX per 1000 patients. CONCLUSION: FOND offers
hospitals in Germany a clinically and economically advantageous




STENTS: 18-MONTH CLINICAL AND ECONOMIC OUTCOMES
OF A CONTROLLED STUDY FORTHE REDUCTION OF
CORONARY RESTENOSIS
McBride D, Brüggenjürgen B, Roll S,Willich SN
Charité University Medical Center, Berlin, Germany
OBJECTIVES: To evaluate the long-term outcomes of serolimus-
eluting stents (SES) in comparison to bare-metal stents (BMS)
in elective treatment of coronary artery disease (CAD).
METHODS: In the prospectiveGERSHWIN study in 35 hospitals
in Germany, CAD patients undergoing percutaneous coronary
intervention (PCI) were electively treated with SES or BMS
(sequential control design with a case : control ratio of 2 : 1).
Standardized questionnaires completed by patients and physicians
at 3, 6, 12, and 18 months following PCI documented major
adverse coronary events (MACE), including death, myocardial
infarct, coronary bypass surgery and re-PCI in target vessel (TVR),
as well as disease-related direct and indirect costs. RESULTS:
From April 2003 until June 2005, 658 patients were treated with
SES (87% male, mean age 63  9) und 294 patients with BMS
(79%male, mean age 64  10). After 18 months, 13% of the SES
cohort and 20% of the BMS cohort had suffered a MACE (p
adjusted < 0.01). Initial hospital costs were signiﬁcantly higher
for SES than for BMS (6001  57 vs. 3913  69 EUR, p
adjusted < 0.01) and the respective 18-month follow-up direct
and indirect costs were similar (7949  462 vs. 8360  554 EUR
p adjusted = 0.455). Over 18 months, total TVR-related and
disease-related costs were higher in SES compared to BMS:
12,876  438 vs. 11,501  525 EUR and 13,950  468 vs.
12,273  562 EUR, respectively, both p adjusted < 0,01. For
TVR costs, the cost-effectiveness of SES was 15,995 EUR per
patient free from MACE and for total disease-related costs,
19,500 EUR. CONCLUSION: In comparison to patients follow-
ing BMS implantation, patients 18 months following implanta-
tion of SES experienced signiﬁcantly fewer MACE. The higher
initial costs for SES compare to BMS were followed by similar
economic consequences in both groups with cost-effectiveness of
under 20,000 EUR per patient free from MACE.
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OBJECTIVES: To evaluate the cost-effectiveness of serolimus-
eluting stents (SES) to bare-metal stents (BMS) in patients with
single-vessel coronary artery disease (SVD) compared with
patients with multi-vessel disease (MVD). METHODS: In the
prospective GERSHWIN study in 35 hospitals in Germany,
patients with coronary artery disease (CAD) undergoing percu-
taneous coronary intervention (PCI) were electively treated with
SES or BMS (sequential control design). Standardized question-
naires completed by patients and physicians through 18 months
following PCI documented major adverse coronary events
(MACE), including death, myocardial infarction, coronary artery
bypass surgery and re-PCI in target vessel, as well as disease-
related direct and indirect costs. RESULTS: From April 2003
until June 2005, 658 patients were treated with SES (87% male,
mean age 63  9) und 294 patients with BMS (79% male, mean
age 64  10). SVD was documented in 34% BMS patients and
29% SES patients. After 18 months, 8% of SES and 25% of BMS
patients with SVD had suffered MACE in comparison to 15% of
SES and 19% of BMS patients with MVD, indicating a difference
in the effect of SES with respect to the underlying CAD status (p
adjusted = 0.023). In SVD, SES and BMS incurred total costs of
EUR 11,832 and 12,399, respectively. In MVD, SES and BMS
incurred total costs of EUR 14,964 and 12,026, respectively (p
adjusted = 0.003). In patients with SVD, the cost-effectiveness of
SES was EUR 12,805 per patient free from MACE compared to
EUR 16,488 in BMS. In patients with MVD, the cost-
effectiveness of SES was EUR 17,522 per patient free from
MACE compared to EUR 14,810 in BMS. CONCLUSION: In
patients with SVD, SES is more cost effective than BMS whereas
in patients with MVD, SES is less cost effective than BMS.
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THE COST-EFFECTIVENESS (COST-UTILITY) OF EPROSARTAN
IN HYPERTENSIVE PATIENTS WITH CEREBROVASCULAR
DISEASE IN BELGIUM, GERMANY, SPAIN, UNITED KINGDOM,
AND SWEDEN
Schwander B1, Lindgren P2, Gradl B3
1Analytica International, Loerrach, Germany, 2I3 innovus, Stockholm,
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OBJECTIVES: The purpose of this study was to evaluate the
relative cost-effectiveness (cost-utility) of the angiotensin II
antagonist eprosartan versus other antihypertensives (nitren-
dipine, perindopril, enalapril) in a secondary prevention setting
(hypertensives with cerebrovascular disease at baseline) in
Belgium, Germany, Spain, UK and Sweden. METHODS: The
HEALTH model (Health Economic Assessment of Life with
Teveten® for Hypertension) is an object-oriented probabilistic
Monte Carlo simulation model. It combines a Framingham-
based risk calculation with a systolic blood pressure approach to
estimate the relative risk reduction of cardiovascular and cere-
brovascular events based on recent meta-analyses. For eprosar-
tan an additional risk reduction was modelled according to the
results of the MOSES study (‘Morbidity and Mortality after
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